China approves first brain chips, aims for industry dominance

China has taken a significant leap by approving the first brain chips for commercial sale, signaling a rapid advancement in neurotechnology. This move contrasts sharply with the more cautious approach seen in the United States and Europe, where clinical trials are still the primary focus. China's aggressive strategy aims to establish industry dominance in the burgeoning field of brain-computer interfaces. The rapid commercialization suggests a strong governmental push to lead in this transformative technology, potentially reshaping the future of human augmentation and medical applications.